WO2007047607A2 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues - Google Patents

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues Download PDF

Info

Publication number
WO2007047607A2
WO2007047607A2 PCT/US2006/040429 US2006040429W WO2007047607A2 WO 2007047607 A2 WO2007047607 A2 WO 2007047607A2 US 2006040429 W US2006040429 W US 2006040429W WO 2007047607 A2 WO2007047607 A2 WO 2007047607A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
retinal
eye
poly
ocular
Prior art date
Application number
PCT/US2006/040429
Other languages
English (en)
French (fr)
Other versions
WO2007047607A3 (en
Inventor
Jeffrey L. Edelman
Kelly M. Harrison
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Priority to EP06826056.1A priority Critical patent/EP1937210B1/en
Priority to JP2008536724A priority patent/JP5745208B2/ja
Priority to AU2006304416A priority patent/AU2006304416B2/en
Priority to KR1020077028609A priority patent/KR101430760B1/ko
Priority to CA2602577A priority patent/CA2602577C/en
Priority to NZ562032A priority patent/NZ562032A/en
Priority to MX2007012061A priority patent/MX2007012061A/es
Priority to BRPI0613401A priority patent/BRPI0613401B8/pt
Priority to MX2012007846A priority patent/MX339797B/es
Publication of WO2007047607A2 publication Critical patent/WO2007047607A2/en
Publication of WO2007047607A3 publication Critical patent/WO2007047607A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PCT/US2006/040429 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues WO2007047607A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP06826056.1A EP1937210B1 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
JP2008536724A JP5745208B2 (ja) 2005-10-18 2006-10-17 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
AU2006304416A AU2006304416B2 (en) 2005-10-18 2006-10-17 Ocular therapy using Glucocorticoid Derivatives selectively penetrating posterior segment tissues
KR1020077028609A KR101430760B1 (ko) 2005-10-18 2006-10-17 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
CA2602577A CA2602577C (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
NZ562032A NZ562032A (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
MX2007012061A MX2007012061A (es) 2005-10-18 2006-10-17 Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
BRPI0613401A BRPI0613401B8 (pt) 2005-10-18 2006-10-17 composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior
MX2012007846A MX339797B (es) 2005-10-18 2006-10-17 Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72820905P 2005-10-18 2005-10-18
US60/728,209 2005-10-18

Publications (2)

Publication Number Publication Date
WO2007047607A2 true WO2007047607A2 (en) 2007-04-26
WO2007047607A3 WO2007047607A3 (en) 2007-11-15

Family

ID=37872252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040429 WO2007047607A2 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Country Status (11)

Country Link
US (5) US8062657B2 (US08062657-20111122-C00005.png)
EP (1) EP1937210B1 (US08062657-20111122-C00005.png)
JP (2) JP5745208B2 (US08062657-20111122-C00005.png)
KR (1) KR101430760B1 (US08062657-20111122-C00005.png)
CN (1) CN101394834A (US08062657-20111122-C00005.png)
AU (1) AU2006304416B2 (US08062657-20111122-C00005.png)
BR (1) BRPI0613401B8 (US08062657-20111122-C00005.png)
CA (1) CA2602577C (US08062657-20111122-C00005.png)
MX (2) MX339797B (US08062657-20111122-C00005.png)
NZ (1) NZ562032A (US08062657-20111122-C00005.png)
WO (1) WO2007047607A2 (US08062657-20111122-C00005.png)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039262A2 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing ophthalmic drug delivery systems
JP2010526780A (ja) * 2007-04-30 2010-08-05 アラーガン、インコーポレイテッド 眼症状を処置するための高粘度高分子組成物
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9849085B2 (en) 2000-04-26 2017-12-26 Psivida Us Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US10174071B2 (en) 2012-05-08 2019-01-08 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
CN101394834A (zh) 2005-10-18 2009-03-25 阿勒根公司 用糖皮质激素衍生物选择性渗透后段组织来治疗眼睛
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
PT2214646T (pt) * 2007-10-05 2021-09-29 Univ Wayne State Dendrímeros para libertação sustentada de compostos
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2515864A4 (en) * 2009-12-23 2013-09-11 Psivida Inc DELAYED RELEASE DELIVERY DEVICES
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
US10501779B2 (en) * 2011-05-12 2019-12-10 President And Fellows Of Harvard College Oligonucleotide trapping
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2015168347A1 (en) 2014-04-30 2015-11-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
CN115350285A (zh) 2014-08-13 2022-11-18 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US20180293360A1 (en) * 2015-10-07 2018-10-11 Genentech, Inc. Systems and methods for predicting vitreal half-life of therapeutic agent-polymer conjugates
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
IL293606A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods of administering a drug to the eye

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661055A1 (en) 1993-12-31 1995-07-05 Laboratorios Cusi, S.A. Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof
WO2004050065A1 (en) 2002-11-27 2004-06-17 Biosante Pharmaceuticals, Inc. Intraocular delivery compositions and methods
US20040171598A1 (en) 2003-02-20 2004-09-02 Bingaman David P. Use of steroids to treat persons suffering from ocular disorders
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050182185A1 (en) 2001-12-12 2005-08-18 Pascal Herve Formulation comprising an ionic compound, a polyionic polymer, and a block copolymer
WO2005107727A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Steroid intraocular implants having an extended sustained release for a period of greater than two months

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
ES2253787T3 (es) 1996-11-05 2006-06-01 The Children's Medical Center Corporation Composiciones para inhibicion de la angiogenesis que comprenden talidomida y un nsaid.
WO1999007418A2 (en) * 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6873524B2 (en) * 2002-08-15 2005-03-29 Audavi Corporation Data storage device
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CN101394834A (zh) * 2005-10-18 2009-03-25 阿勒根公司 用糖皮质激素衍生物选择性渗透后段组织来治疗眼睛
JP2007309763A (ja) 2006-05-18 2007-11-29 Sumitomo Electric Ind Ltd 電線の表面欠陥検出装置

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661055A1 (en) 1993-12-31 1995-07-05 Laboratorios Cusi, S.A. Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof
US20050182185A1 (en) 2001-12-12 2005-08-18 Pascal Herve Formulation comprising an ionic compound, a polyionic polymer, and a block copolymer
WO2004050065A1 (en) 2002-11-27 2004-06-17 Biosante Pharmaceuticals, Inc. Intraocular delivery compositions and methods
US20040171598A1 (en) 2003-02-20 2004-09-02 Bingaman David P. Use of steroids to treat persons suffering from ocular disorders
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005107727A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Steroid intraocular implants having an extended sustained release for a period of greater than two months

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EDELMAN ET AL., EXP. EYE RES., vol. 80, 2005, pages 249 - 258

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849085B2 (en) 2000-04-26 2017-12-26 Psivida Us Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AU2008302309B2 (en) * 2005-10-18 2014-09-25 Allergan, Inc. Steroid containing ophthalmic drug delivery systems
JP2016040313A (ja) * 2007-04-30 2016-03-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼症状を処置するための高粘度高分子組成物
JP2014005288A (ja) * 2007-04-30 2014-01-16 Allergan Inc 眼症状を処置するための高粘度高分子組成物
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
JP2010526780A (ja) * 2007-04-30 2010-08-05 アラーガン、インコーポレイテッド 眼症状を処置するための高粘度高分子組成物
WO2009039262A3 (en) * 2007-09-21 2009-05-07 Allergan Inc Steroid containing ophthalmic drug delivery systems
JP2015091858A (ja) * 2007-09-21 2015-05-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ステロイド含有薬物送達システム
WO2009039262A2 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing ophthalmic drug delivery systems
JP2010540447A (ja) * 2007-09-21 2010-12-24 アラーガン、インコーポレイテッド ステロイド含有薬物送達システム
US10174071B2 (en) 2012-05-08 2019-01-08 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9822142B2 (en) 2012-05-08 2017-11-21 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10954263B2 (en) 2012-05-08 2021-03-23 Nicox Ophthalmics, Inc Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US11814408B2 (en) 2012-05-08 2023-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Also Published As

Publication number Publication date
US10188665B2 (en) 2019-01-29
CA2602577A1 (en) 2007-04-26
MX2007012061A (es) 2007-12-13
US20140357609A1 (en) 2014-12-04
AU2006304416B2 (en) 2013-03-28
US20160158249A1 (en) 2016-06-09
EP1937210B1 (en) 2017-05-31
NZ562032A (en) 2011-11-25
CN101394834A (zh) 2009-03-25
BRPI0613401B8 (pt) 2021-05-25
CA2602577C (en) 2015-03-31
BRPI0613401B1 (pt) 2020-08-04
BRPI0613401A2 (pt) 2011-01-11
MX339797B (es) 2016-06-10
US8062657B2 (en) 2011-11-22
US9259429B2 (en) 2016-02-16
US20120065178A1 (en) 2012-03-15
US20180125861A1 (en) 2018-05-10
KR101430760B1 (ko) 2014-08-19
JP2014028855A (ja) 2014-02-13
JP2009511632A (ja) 2009-03-19
EP1937210A2 (en) 2008-07-02
WO2007047607A3 (en) 2007-11-15
KR20080055749A (ko) 2008-06-19
US20070088014A1 (en) 2007-04-19
US9820995B2 (en) 2017-11-21
US8840872B2 (en) 2014-09-23
JP5745208B2 (ja) 2015-07-08
AU2006304416A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
US10188665B2 (en) Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
CA2700072C (en) Steroid containing drug delivery systems
US8571802B2 (en) Method for determining optimum intraocular locations for drug delivery systems
RU2440102C2 (ru) Системы доставки лекарственного средства внутрь глаза
TWI332846B (en) Ocular implant made by a double extrusion process
US20050271705A1 (en) Retinoid-containing sustained release intraocular drug delivery system and related methods
US20070212395A1 (en) Ocular therapy using sirtuin-activating agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680016479.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2602577

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006304416

Country of ref document: AU

Ref document number: 562032

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012061

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 7615/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006304416

Country of ref document: AU

Date of ref document: 20061017

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2006826056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006826056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077028609

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008536724

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0613401

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080115